The Sustain 3 study compared the treatment outcomes of Ozempic with Bydureon (Exenatide ER). Both of these drugs are once weekly GLP-1 analogues although Bydureon is based in the Exendin molecule rather than human GLP-1) used in the treatment of type 2 diabetes. Exendin is only 55% similar to human GLP-1.
Ozempic compared to Bydureon led to:
lower blood sugars based on HbA1c compared of about 0.6% (-1.5%vs 0.9%).
Weight loss with Ozempic was 5.6kg vs 1.9kg with Bydureon.
More people had HbA1c below the 7% to suggest safer sugar levels.